Here's How Much You'd Have If You Invested $1000 in Insulet a Decade Ago

Insulet’s 10-year performance shows a $1,000 investment made in July 2016 growing to $5,022.73 by July 13, 2026 (+402.27% total gain). For 2025, Drug Delivery revenues fell to $34.1M (-12.3% y/y) as Omnipod sales remain the core driver (86% sold via intermediaries). In early 2026, first-quarter results beat expectations and management raised full-year revenue growth guidance while maintaining its margin expansion plan; near-term upside drivers include Omnipod 5 algorithm enhancements (including a 100 mg/dL target option and Libre 3 Plus integration) and international rollout. Shares have risen 7.74% over the past four weeks, though risks include execution/cost pressures from a voluntary device correction and potential gross-margin pressure during product transitions.

Analysis

PODD still looks like a quality-growth compounder, but the market is increasingly paying for execution rather than just top-line growth. The important mechanism is that recurring pod replacement plus broader pharmacy access can support a higher multiple only if margin expansion survives the device-correction reset; otherwise the stock starts to trade like a medtech with operational risk, not a software-like annuity. That makes the next 1-2 earnings prints more important than the next 12 months of product-launch headlines.

The cleaner relative-value read is that PODD’s share gains should come at the expense of smaller diabetes hardware names, especially TNDM, where any perception of slower switching or weaker ecosystem integration can widen the valuation gap. By contrast, AMGN’s exposure here is more of a sidecar than a thesis driver; the drug-delivery line is too small to move the equity, so it is not a compelling long/short leg on its own. Second-order, the bigger risk is reimbursement scrutiny: if payers push back on device economics, the entire premium-growth cohort can de-rate together.

Contrarian view: consensus may be underestimating execution drag from product transitions and shipping/input costs just as management is asking investors to pay up for growth visibility. If gross margin fails to expand through the next cycle, the rerating case breaks quickly. Time horizon matters: the stock can stay strong for days on momentum, but the real falsifier is a 2026 guide revision or a quarter where growth is intact but margin progression stalls.

Key Decisions for Investors

• Initiate a relative-value long PODD / short TNDM pair over the next 1-3 months; thesis is better channel access and more durable recurring revenue, with downside if PODD’s correction or reimbursement issues slow adoption.
• Do not chase PODD after the recent run; wait for a 3-5% pullback or a post-earnings setup to add, because the multiple is now sensitive to any margin disappointment.
• Set a risk alert on PODD’s next print: if gross margin expansion is below expectations or FY26 margin guidance is reduced, trim/exit rather than averaging down.
• No standalone trade in AMGN from this item; treat the drug-delivery exposure as immaterial unless future disclosure shows a materially larger revenue contribution.
• If payer scrutiny or competitive pressure intensifies, consider hedging PODD with a basket short of higher-multiple medtech growth names rather than a broad healthcare index short.